Moderate riskFDA DrugClass II

Pfizer Dopamine HCl injection recalled for lack of sterility assurance

Pfizer has recalled one lot of Dopamine HCl injection (40 mg/mL) distributed nationwide due to a lack of assurance of sterility. The affected lot is NL5230, with an expiration date of October 2027. This is a precautionary measure to ensure patient safety.

From the FDA notice · Read the official notice ↗

What to do

  1. Check your facility's dopamine stock for lot number NL5230.
  2. Do not use vials from this lot.
  3. Contact Pfizer or your supplier for return or replacement instructions.
  4. Report any adverse events to the FDA MedWatch program.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
66 Hudson Blvd, N/A, Manhattan, NY, United States
Classification
Class II
Recall number
D-0853-2026

In the FDA's words

Description
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01. Lack of Assurance of Sterility Lot # NL5230, Exp Date:10/2027 Distribution: US Nationwide. Affected quantity: N/A
Hazard
Lack of Assurance of Sterility

More from Pfizer

Related topics

SterilityDrugsSold nationwideMore from FDA Drug